
NASDAQ:VTRS
This summary was created by AI, based on 2 opinions in the last 12 months.
Viatris (VTRS-Q) has emerged as a player in the healthcare sector after its spin-off from Pfizer. The company is characterized by low growth, prompting some experts to suggest that it operates on a tight leash in terms of corporate management. While one expert expresses a positive outlook on its current positioning, emphasizing the need for an increased focus on shareholder value, another highlights its small cap status and limited market presence. The stock is trading at a relatively low price-to-earnings (PE) ratio of 7-8x, indicating potential attractiveness for value investors. However, the overall assessment reflects a cautious approach, advocating for the pursuit of companies that are available at a bargain in the healthcare market.
Brand new company from the merger if Mylan and Upjohn. Trades at 6x earnings and nobody has covered this. This stock will trade at 10-11x earnings, nearly doubling. This is his most compelling top pick today. The company is already generating profits and cash flow. They make Xoloft, Viagra, Lipotor mostly from Upjohn. They also have a pipeline of new drugs company. Seasoned managers. (Analysts’ price target is $22.43)